Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.
Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M. Shiota M, et al. Among authors: tatarano s. Endocr Relat Cancer. 2023 Jun 1;30(7):e230044. doi: 10.1530/ERC-23-0044. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37079309
Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Osaki Y, Tashiro Y, Uegaki M, Ogawa O, Kitamura H, Nishiyama H. Ito K, et al. Among authors: tatarano s. Cancer Med. 2021 May;10(10):3188-3196. doi: 10.1002/cam4.3863. Epub 2021 May 1. Cancer Med. 2021. PMID: 33931987 Free PMC article.
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Kobayashi M, et al. BJU Int. 2022 Aug;130(2):226-234. doi: 10.1111/bju.15510. Epub 2021 Jul 6. BJU Int. 2022. PMID: 34110696
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Shiota M, et al. Among authors: tatarano s. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. Cancer Immunol Immunother. 2023. PMID: 36729213 Free PMC article.
Real-world treatment outcomes of patients with penile cancer in the Kyushu-Okinawa area of Japan in the pre-guideline era.
Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T. Yamaguchi T, et al. Among authors: tatarano s. Jpn J Clin Oncol. 2023 Aug 30;53(9):837-844. doi: 10.1093/jjco/hyad053. Jpn J Clin Oncol. 2023. PMID: 37282601
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators. Blas L, et al. Among authors: tatarano s. Int J Urol. 2023 Sep;30(9):788-796. doi: 10.1111/iju.15265. Epub 2023 Aug 1. Int J Urol. 2023. PMID: 37528632
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S. Yokomizo A, et al. Among authors: tatarano s. Int J Urol. 2024 Apr;31(4):362-369. doi: 10.1111/iju.15371. Epub 2023 Dec 26. Int J Urol. 2024. PMID: 38148124 Clinical Trial.
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study.
Shiota M, Tanegashima T, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Yokomizo A, Naito S, Eto M. Shiota M, et al. Among authors: tatarano s. Prostate Cancer Prostatic Dis. 2024 Feb 17. doi: 10.1038/s41391-024-00808-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38368501
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M. Tanegashima T, et al. Among authors: tatarano s. J Immunol. 2024 May 17:ji2300308. doi: 10.4049/jimmunol.2300308. Online ahead of print. J Immunol. 2024. PMID: 38758119
66 results